Veracyte | VCYT - Betriebsaufwand





Betriebsaufwand Veränderung Datum
Agenus USD -221.22M 241.03M 2026-03
Agilent USD 1.44B 9M 2026-03
Anika Therapeutics USD 133.9M 103.93M 2026-03
Arrowhead Research USD 215M 8.23M 2026-03
Bruker USD 813.2M 87.7M 2026-03
Heron Therapeutics USD 40.55M 1.46M 2025-12
Illumina USD 852M 51M 2026-03
Intrexon USD 61.56M 26.1M 2024-06
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Laboratory Of America USD 3.13B 6.3M 2026-03
Ligand Pharmaceuticals USD 34.35M 5.27M 2026-03
Myriad Genetics USD 212.8M 16.2M 2025-12
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Roche Holding CHF 21.01B 10.84B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Siemens EUR 16.57B 2.29B 2025-12
Sonic Healthcare AUD 4.23B 2.14B 2024-12
Thermo Fisher Scientific USD 9.81B 716M 2026-06
Veracyte USD 119.99M 3.99M 2026-03
Waters USD 1.12B 457.15M 2026-03